Myriad genetics: Patent law and genetic testing

Rimmer, Matthew (2003) Myriad genetics: Patent law and genetic testing. European Intellectual Property Review, 25(1), pp. 20-33.

View at publisher

Abstract

This paper considers the legal challenges to the legal validity of the patents held by Myriad Genetics in respect of genetic testing for breast cancer and ovarian cancer. It argues that broad-based patents on gene sequences and medical diagnostics will have a harmful effect upon access to patient care, genetic research, and the administration of public health care.

Impact and interest:

Citation counts are sourced monthly from Scopus and Web of Science® citation databases.

These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.

Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.

ID Code: 86807
Item Type: Journal Article
Refereed: No
Keywords: Patent law, novelty inventive, compulsory licensing, ethical objections, research exemption, genetic testing, inventorship, European Biotechnology Directive, step utility, Intellectual Property and Innovation Law Research Group
ISSN: 0142-0461
Divisions: Current > QUT Faculties and Divisions > Faculty of Law
Current > Schools > School of Law
Deposited On: 23 Sep 2015 01:56
Last Modified: 23 Sep 2015 01:56

Export: EndNote | Dublin Core | BibTeX

Repository Staff Only: item control page